Testing a gene-editing treatment, CTX340, in adults with high blood pressure
Tests CTX340, a gene-editing treatment, in adults with uncontrolled hypertension.
Plain-language title generated from the registry record
Registry title: A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension
Key facts
- Where
- Melbourne, AustraliaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07758634, who can take part
Where in Australia
- MelbourneMelbourne, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CRISPR Therapeutics AG
- Trial code
- NCT07758634
- Record updated
- 11 August 2026
- Original description
A Study of CTX340 in Participants with Uncontrolled Hypertension.Read full original descriptionShow less
A Phase 1/2 Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety, Tolerability, and Efficacy of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX340) for In Vivo Editing of the Angiotensinogen (AGT) Gene in Participants With Hypertension
A Study of CTX340 in Participants with Uncontrolled Hypertension.
Inclusion: Age: ≥18 and ≤75 years; Body mass index ≤40 kg/m2; 24-hour mean ambulatory blood pressure monitoring (ABPM) systolic blood pressure (SBP) measurement of ≥130 mm Hg but ≤160 mm Hg despite treatment; Be on treatment with ≥4 antihypertensive therapies at effective doses, of which ≥1 must be a diuretic; Participants who at any point had childbearing potential must currently be postmenopausal; All participants capable of producing sperm must agree to the use of an acceptable method of effective contraception and their partners with childbearing potential should also agree to use an effective method of contraception.
Exclusion: Participants with vascular cause of hypertension which may be amendable to revascularization; Participants with treatable/reversible causes of uncontrolled hypertension; History of renal artery denervation within past 12 months; Evidence of liver disease; History of a significant coagulation disorder; Uncontrolled or untreated thyroid disease; Serum aldosterone and direct renin concentration (or plasma renin activity [PRA]) suggestive of primary aldosteronism; Complete blood count (CBC) outside the specified ranges per protocol; Mean diastolic blood pressure (DBP) ≤65 mm Hg on screening ABPM; Orthostatic hypotension.